Open Access
Med Sci (Paris)
Volume 35, Number 12, Décembre 2019
Anticorps monoclonaux en thérapeutique
Page(s) 1146 - 1152
Section Les anticorps biosimilaires
Published online 06 January 2020
  1. Reichert JM, Beck A. European medicines agency workshop on biosimilar monoclonal antibodies. MAbs 2009 ; 1: 394–416. [CrossRef] [PubMed] [Google Scholar]
  2. Beck A, Reichert JM. Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry. MAbs 2013 ; 5: 621–623. [CrossRef] [PubMed] [Google Scholar]
  3. Ayoub D, Jabs W, Resemann A, et al. Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques. MAbs 2013 ; 699–710. [CrossRef] [PubMed] [Google Scholar]
  4. Gahoual R, Biacchi M, Chicher J, et al. Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry. MAbs 2014 ; 6: 1464–1473. [CrossRef] [PubMed] [Google Scholar]
  5. Beck A, Wagner-Rousset E, Wurch T, et al. Anticorps thérapeutiques et dérivés: une palette de structures pour une pléthore d’indications. Quel format et quelle glycosylation choisir ? Pour quelles applications ?. Med Sci (Paris) 2009 ; 25: 1024–1032. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  6. Beck A.. Biosimilar, biobetter and next generation therapeutic antibodies. MAbs 2011 ; 3: 107–110. [CrossRef] [PubMed] [Google Scholar]
  7. Beck A, Sanglier-Cianférani S, Van Dorsselaer A. Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry. Anal Chem 2012 ; 84: 4637–4646. [CrossRef] [PubMed] [Google Scholar]
  8. Beck A, Debaene F, Diemer H, et al. Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies. J Mass Spectrom 2015 ; 50: 285–297. [CrossRef] [PubMed] [Google Scholar]
  9. Ambrogelly A, Gozo S, Katiyar A, et al. Analytical comparability study of recombinant monoclonal antibody therapeutics. MAbs 2018 ; 10: 513–538. [CrossRef] [PubMed] [Google Scholar]
  10. van Aerts L, De Smet K, Reichmann G, et al. Biosimilars entering the clinic without animal studies. A paradigm shift in the European Union. MAbs 2014; 6: 1155–62. [CrossRef] [PubMed] [Google Scholar]
  11. Rahalkar H, Cetintas HC, Salek S. Quality, non-clinical and clinical considerations for biosimilar monoclonal antibody development: EU, WHO, USA, Canada, and BRICS-TM regulatory guidelines. Front Pharmacol 2018; 9. [Google Scholar]
  12. Lee KH, Lee J, Bae JS, et al. Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product. MAbs 2018 ; 10: 380–396. [CrossRef] [PubMed] [Google Scholar]
  13. Nupur N, Chhabra N, Dash R, et al. Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study. MAbs 2018 ; 10: 143–158. [CrossRef] [PubMed] [Google Scholar]
  14. Lee N, Lee JAJ, Yang H, et al. Evaluation of similar quality attribute characteristics in SB5 and reference product of adalimumab. MAbs 2018 ; 11: 129–144. [CrossRef] [PubMed] [Google Scholar]
  15. Hassett B, Scheinberg M, Castañeda-Hernández G, et al. Variability of intended copies for etanercept (Enbrel®): data on multiple batches of seven products. MAbs 2018 ; 10: 166–176. [CrossRef] [PubMed] [Google Scholar]
  16. Beck A, Wagner-Rousset E, Bussat MC, et al. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr Pharm Biotechnol 2008 ; 9: 482–501. [CrossRef] [PubMed] [Google Scholar]
  17. Largy E, Cantais F, Van Vyncht G, et al. Orthogonal liquid chromatography-mass spectrometry methods for the comprehensive characterization of therapeutic glycoproteins, from released glycans to intact protein level. J Chromatogr A 2017 ; 1498: 128–146. [CrossRef] [PubMed] [Google Scholar]
  18. Fang J, Doneanu C, Alley WRJ, et al. Advanced assessment of the physicochemical characteristics of Remicade® and Inflectra® by sensitive LC/MS techniques. MAbs 2016 ; 8: 1021–1034. [CrossRef] [PubMed] [Google Scholar]
  19. Lee C, Jeong M, Lee JAJ, et al. Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®. MAbs 2017 ; 9: 968–977. [CrossRef] [PubMed] [Google Scholar]
  20. Brachet G, Respaud R, Arnoult C, et al. Increment in drug loading on an antibody-drug conjugate increases its binding to the human neonatal Fc receptor in vitro. Mol Pharm 2016 ; 13: 1405–1412. [CrossRef] [PubMed] [Google Scholar]
  21. Seo N, Polozova A, Zhang M, et al. Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab. MAbs 2018 ; 10: 678–691. [CrossRef] [PubMed] [Google Scholar]
  22. Liu J, Eris T, Li C, et al. Assessing analytical similarity of proposed amgen biosimilar ABP 501 to Adalimumab. BioDrugs 2016 ; 30: 321–338. [CrossRef] [PubMed] [Google Scholar]
  23. Magnenata L, Palmeseb A, Fremauxc C ele, et al. Demonstration of physicochemical and functional similarity between the proposed. MAbs 2017; 9: 127–39. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.